没有心力衰竭的患者心肌梗塞后的β- 阻塞剂
John Munkhaugen1,2, Anna Meta D Kristensen3, Sigrun Halvorsen4,5
1Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.
The New England journal of medicine
|September 1, 2025
概括
心肌梗塞后的β- 阻断剂治疗显著降低了被保存的喷射分数患者的死亡或重大心血管不良事件的风险. 这一发现支持在心肌梗塞后治疗中使用β抑制剂.
科学领域:
- 心脏病学
- 临床试验
- 药理学
背景情况:
- 已确立的β-阻断剂证据早于现代的再注血和二次预防策略.
- 目前的指导方针要求更新心肌梗塞后治疗的证据.
研究的目的:
- 评估心脏病发作后的β抑制剂治疗的长期疗效.
- 评估β抑制剂对死亡率和主要心血管不良事件 (MACE) 的影响,患者左心室排气分数 (LVEF) ≥40%.
主要方法:
- 在丹麦和挪威进行盲目的终点评估的开放性随机试验.
- 在14天内,有5574名心脏病发作和LVEF≥40%的患者被随机分为1:1接受β- 阻断剂或不服用β- 阻断剂.
- 主要终点:综合所有死因或MACE (心脏病发作,再血管,中风,心力衰竭,心室节律失常).
主要成果:
- 随访时间中位数为3. 5年.
- 在非β抑制剂组 (n=2783) 中,主要终点事件为14. 2%,而非β抑制剂组 (n=2791) 中为16. 3% (HR为0. 85;P=0. 03).
- 使用β- 阻断剂观察到心脏病发作风险降低 (HR 0. 73);无任何原因死亡或其他MACE成分的显著差异. 安全性结果相似.
结论:
- 在LVEF患者中,β抑制剂治疗显著降低了死亡或MACE的风险≥40%.
- 结果支持继续使用β- 阻断剂作为MI后二次预防的基石.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:28Antihypertensive Drugs: Types of β-Blockers
863
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863
01:16Antianginal Drugs: Nitrates and β-Blockers
749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597